ABSTRACT

During a recent webinar on COVID-19 that focused on caregivers for patients with cancer, Shera Dubitsky, MEd, MA, Senior Advisor to Sharsheret’s Medical Advisory Board, addressed the topic of traversing the uncharted territory of COVID-19, focusing on caregivers and family members of women with breast or ovarian cancer.

“These are very unprecedented times, and we understand the challenge,” said Executive Director Elana Silber, MBA, explaining that Sharsheret’s longtime model is one of remote support.

Summary

Pevonedistat plus azacitidine increased overall survival, event-free survival and response rates compared with azacytidine alone in higher-risk

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease (aGVHD), according to data from the REACH2 trial presented at the 25th Annual European Hematology Congress.

(continued at link)

The novel C3 inhibitor pegcetacoplan led to a significant improvement in